13 research outputs found

    Π•Ρ„Π΅ΠΊΡ‚ΠΎΡ‚ Π½Π° Π²Π°Π»ΠΏΡ€ΠΎΠ°Ρ‚ Π½Π° ΠΊΠΎΡ€Ρ‚ΠΈΠΊΠ°Π»Π½Π°Ρ‚Π° Π΅Π»Π΅ΠΊΡ‚Ρ€ΠΎΠ³Π΅Π½Π΅Π·Π°

    Get PDF
    Π”Π° ΠΏΠΎΠΊΠ°ΠΆΠ΅ΠΌΠ΅ Π½Π΅ΠΊΠΎΠΈ наши ΠΊΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠΈ искуства Π·Π° Π΅Ρ„Π΅ΠΊΡ‚ΠΎΡ‚ Π½Π° Ρ…Ρ€ΠΎΠ½ΠΈΡ‡Π½ΠΈΠΎΡ‚ Ρ‚Ρ€Π΅Ρ‚ΠΌΠ°Π½ со Π²Π°Π»ΠΏΡ€ΠΎΡ‚ Π½Π° ΠΊΠΎΡ€Ρ‚ΠΈΠΊΠ°Π»Π½Π°Ρ‚Π° Π΅Π»Π΅ΠΊΡ‚Ρ€ΠΎΠ³Π΅Π½Π΅Π·Π°, ΠΊΠΎΠ΅ досСга ΠΌΠ½ΠΎΠ³Ρƒ ΠΌΠ°Π»ΠΊΡƒ Π΅ студирано ΠΈΠ°ΠΊΠΎ Π»Π΅ΠΊΠΎΡ‚ Π΅ Π²ΠΎ ΡƒΠΏΠΎΡ‚Ρ€Π΅Π±Π° ΠΎΠ΄ 1964 Π³ΠΎΠ΄ΠΈΠ½Π°

    Transcatheter Closure of Patent Foramen Ovale: A Single Center Experience

    Get PDF
    BACKGROUND: Percutaneous transcatheter closure (PTC) of patent foramen ovale (PFO) is implicated in cryptogenic stroke, transitional ischemic attack (TIA) and treatment of a migraine.AIM: Our goal was to present our experience in the interventional treatment of PFO, as well as to evaluate the short and mid-term results in patients with closed PFO.MATERIAL AND METHODS: Transcatheter closure of PFO was performed in 52 patients (67.3% women, mean age 40.7 ± 11.7 years). Patients were interviewed for subjective grading of the intensity of headaches before and after the PFO closure.RESULTS: During 2 years of follow-up, there was no incidence of new stroke, TIA and/or syncope. Follow-up TCD performed in 35 patients showed complete PFO closure in 20 patients (57.1%). Out of 35 patients, 22 (62.9%) reported having a migraine before the procedure with an intensity of headaches at 8.1 ± 1.9 on a scale from 1 to 10. During 2 years of follow-up, symptoms of a migraine disappeared in 4 (18.2%) and the remaining 18 patients reported the significant decrease in intensity 4.8 ± 2.04 (p = 0.0001). In addition, following PFO closure the incidence of the headaches decreased significantly (p = 0.0001).CONCLUSIONS: Percutaneous transcatheter closure of PFO is a safe and effective procedure showing mid-term relief of neurological symptoms in patients as well as significant reduction of migraine symptoms

    Evoked potentials in evaluation of solcoseryl (actihamly) effects in the treatment of cerebral atrophic processies

    Get PDF
    Twenty-five patients with cerebral atrophic processes, either local or diffuse, of various etiology proved by computerized tomography were investigated and treated

    ΠΠ΅Π²Ρ€ΠΎΡ„ΠΈΠ·ΠΈΠΎΠ»ΠΎΡˆΠΊΠΈ студии Π²ΠΎ ΠΈΡΠΏΠΈΡ‚ΡƒΠ²Π°ΡšΠ΅Ρ‚ΠΎ Π½Π° Ρ„Π°Ρ€ΠΌΠ°ΠΊΠΎΠΊΠΈΠ½Π΅Ρ‚ΠΈΠΊΠ°Ρ‚Π° Π½Π° Π°Π½Ρ‚ΠΈΠ΅ΠΏΠΈΠ»Π΅ΠΏΡ†ΠΈΡ‚Π΅

    Get PDF
    Π¦Π΅Π»: Π”Π° сС ΠΏΠΎΠΊΠ°ΠΆΠ΅ Π΄Π΅ΠΊΠ° Ρ†Π΅Ρ€Π΅Π±Ρ€Π°Π»Π½ΠΈΡ‚Π΅ Π΅Π²ΠΎΡ†ΠΈΡ€Π°Π½ΠΈ ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΡ˜Π°Π»ΠΈ сС ΠΊΠ°ΠΊΠΎ ΠΎΠ±Ρ˜Π΅ΠΊΡ‚ΠΈΠ²Π΅Π½ ΠΈΠ½Π΄ΠΈΠΊΠ°Ρ‚ΠΎΡ€ Π²ΠΎ Ρ„Π°Ρ€ΠΌΠ°ΠΊΠΎΠΊΠΈΠ½Π΅Ρ‚ΠΈΠΊΠ°Ρ‚Π° Π½Π° Π°Π½Ρ‚ΠΈΠ΅ΠΏΠΈΠ»Π΅ΠΏΡ†ΠΈΡ‚Π΅

    ГСнСтски ΠΈ Π½Π΅Π²Ρ€ΠΎΡ„ΠΈΠ·ΠΈΠΎΠ»ΠΎΡˆΠΊΠΈ ΠΈΡΡ‚Ρ€Π°ΠΆΡƒΠ²Π°ΡšΠ° кај ΠΌΠΈΠ³Ρ€Π΅Π½Π°

    Get PDF
    ΠœΠΈΠ³Ρ€Π΅Π½Π°Ρ‚Π° ΠΈΠ°ΠΊΠΎ Π΅ ΠΏΠΎΠ·Π½Π°Ρ‚Π° ΡƒΡˆΡ‚Π΅ ΠΎΠ΄ Π°Π½Ρ‚ΠΈΡ‡ΠΊΠΈΡ‚Π΅ Π²Ρ€Π΅ΠΌΠΈΡšΠ° Π΄ΠΎ дСнСс Ρ„ΠΈΠ·ΠΈΠΎΠΏΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΈΡ˜Π°Ρ‚Π° Π½Π° ΠΌΠΈΠ³Ρ€Π΅Π½ΠΏΠ·Π½ΠΈΠΎΡ‚ Π½Π°ΠΏΠ°Π΄ останува Π΅Π½ΠΈΠ³ΠΌΠ°. Π‘ΠΏΠΎΡ€Π΅Π΄ статистиката 23 ΠΌΠΈΠ»ΠΈΠΎΠ½ΠΈ АмСриканци страдаат ΠΎΠ΄ ΠΌΠΈΠ³Ρ€Π΅Π½Π°

    ΠΠ΅Π²Ρ€ΠΎΡ„ΠΈΠ·ΠΈΠΎΠ»ΠΎΡˆΠΊΠΈ ΠΈ гСнСтски ΠΈΡΡ‚Ρ€Π°ΠΆΡƒΠ²Π°ΡšΠ° кај ΠΌΠΈΠ³Ρ€Π΅Π½Π°

    Get PDF
    Π¦Π΅Π»: Π”Π° сС ΠΎΡ‚ΠΊΡ€ΠΈΡ˜Π°Ρ‚ Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΎΠ½Π°Π»Π½ΠΈΡ‚Π΅ Ρ€Π°ΡΡ‚Ρ€ΠΎΡ˜ΡΡ‚Π²Π° кај Π±ΠΎΠ»Π½ΠΈ со ΠΌΠΈΠ³Ρ€Π΅Π½Π° со помош Π½Π° Π½Π΅Π²Ρ€ΠΎΡ„ΠΈΠ·ΠΈΠΎΠ»ΠΎΡˆΠΊΠΈΡ‚Π΅ ΠΈΡΡ‚Ρ€Π°ΠΆΡƒΠ²Π°ΡšΠ°, ΠΊΠ°ΠΊΠΎ ΠΈ Ρ„Π°ΠΌΠΈΠ»ΠΈΡ˜Π°Ρ€Π½Π°Ρ‚Π° Π΅ΠΊΡΠΏΡ€Π΅ΡΠΈΡ˜Π° ΠΌΠΈΠ³Ρ€Π΅Π½Π°Ρ‚Π°, Π½Π°Ρ‡ΠΈΠ½ΠΎΡ‚ Π½Π° Π½Π°ΡΠ»Π΅Π΄ΡƒΠ²Π°ΡšΠ΅Ρ‚ΠΎ ΠΈ Π΅Π²Π΅Π½Ρ‚ΡƒΠ°Π»Π½ΠΈΡ‚Π΅ хромозомски Π°Π±Π΅Ρ€Π°Ρ†ΠΈΠΈ кај случаи Π½Π° Ρ„Π°ΠΌΠΈΠ»ΠΈΡ˜Π°Ρ€Π½Π° ΠΌΠΈΠ³Ρ€Π΅Π½Π°, која сС Ρ˜Π°Π²ΡƒΠ²Π° кај повСќС Ρ‡Π»Π΅Π½ΠΎΠ²ΠΈ Π²ΠΎ Π΅Π΄Π½Π° Ρ„Π°ΠΌΠΈΠ»ΠΈΡ˜Π°

    Somatosensory evoked potentials in patients with thalamic pain

    Get PDF
    The aim of study was to examine how to the Somatosensory evoked potentials are affected in patients with cerebrovascular thalamic lesions and to correlate the findings with sensory abnormalities

    Π˜ΠΌΡƒΠ½ΠΎΠ³Π΅Π½Π΅Ρ‚ΡΠΊΠΈ ΠΈΡΡ‚Ρ€Π°ΠΆΡƒΠ²Π°ΡšΠ° кај ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈ со СпилСпсија

    Get PDF
    ΠŸΠΎΡΠ»Π΅Π΄Π½ΠΈΡ‚Π΅ дСсСт Π³ΠΎΠ΄ΠΈΠ½ΠΈ ΠšΠ»ΠΈΠ½ΠΈΠΊΠ°Ρ‚Π° Π·Π° Π½Π΅Π²Ρ€ΠΎΠ»ΠΎΠ³ΠΈΡ˜Π° Π²ΠΎ соработка со Π˜Π½ΡΡ‚ΠΈΡ‚ΡƒΡ‚ΠΎΡ‚ Π·Π° Ρ‚Ρ€Π°Π½ΡΡ„ΡƒΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ˜Π°, Π˜Π½ΡΡ‚ΠΈΡ‚ΡƒΡ‚ΠΎΡ‚ Π·Π° ΠΊΠ»ΠΈΠ½ΠΈΡ‡ΠΊΠ° Π±ΠΈΠΎΡ…Π΅ΠΌΠΈΡ˜Π° ΠΈ Π˜Π½ΡΡ‚ΠΈΡ‚ΡƒΡ‚ΠΎΡ‚ Π·Π° биологија ΠΏΡ€ΠΈ ΠΠΊΠ°Π΄Π΅ΠΌΠΈΡ˜Π°Ρ‚Π° Π·Π° Π½Π°ΡƒΠΊΠ° спровСдоа имуногСнСтски ΠΈΡΡ‚Ρ€Π°ΠΆΡƒΠ²Π°ΡšΠ° кај ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈ со СпилСпсија

    Somatosensory evoked potentials in deaferentation pain

    Get PDF
    The aim of study was to examine how to the Somatosensory evoked potentials ( SEPs) are affected in patients with cerebrovascular thalamic lesions and to correlate the findings with sensory abnormalities

    EEG changes in patients with Parkinson disease and epileptic attacks

    Get PDF
    Π•Π•Π“-ΠΎΡ‚ Π΅ ΠΌΠ½ΠΎΠ³Ρƒ Π²Π°ΠΆΠ½Π° Π΄ΠΈΡ˜Π°Π³Π½ΠΎΡΡ‚ΠΈΡ‡ΠΊΠ° ΠΌΠ΅Ρ‚ΠΎΠ΄Π° ΡˆΡ‚ΠΎ сС ΠΏΡ€ΠΈΠΌΠ΅Π½ΡƒΠ²Π° кај ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈΡ‚Π΅ со СпилСпсија. Π•Π•Π“ ΠΏΡ€ΠΎΠΌΠ΅Π½ΠΈΡ‚Π΅ кај ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΈΡ‚Π΅ со паркинсонизам ΠΈ со СпилСпсија сС сС ΡƒΡˆΡ‚Π΅ Π½Π΅Π΄ΠΎΠ²ΠΎΠ»Π½ΠΎ ΠΏΠΎΠ·Π½Π°Ρ‚ΠΈ ΠΈ Π½Π΅ΠΎΡ‡Π΅ΠΊΡƒΠ²Π°Π½ΠΈ
    corecore